JP5221355B2 - 治療及び診断用途のための選択的αvβ3レセプターペプチドアンタゴニスト - Google Patents
治療及び診断用途のための選択的αvβ3レセプターペプチドアンタゴニスト Download PDFInfo
- Publication number
- JP5221355B2 JP5221355B2 JP2008534912A JP2008534912A JP5221355B2 JP 5221355 B2 JP5221355 B2 JP 5221355B2 JP 2008534912 A JP2008534912 A JP 2008534912A JP 2008534912 A JP2008534912 A JP 2008534912A JP 5221355 B2 JP5221355 B2 JP 5221355B2
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- amino acid
- peptide
- integrin
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 38
- 239000005557 antagonist Substances 0.000 title claims description 10
- 230000001225 therapeutic effect Effects 0.000 title description 2
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 title 1
- 102000006495 integrins Human genes 0.000 claims description 24
- 108010044426 integrins Proteins 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 23
- 235000001014 amino acid Nutrition 0.000 claims description 22
- 150000001413 amino acids Chemical class 0.000 claims description 19
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical group NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 10
- 210000004899 c-terminal region Anatomy 0.000 claims description 8
- 201000001441 melanoma Diseases 0.000 claims description 8
- 108010091748 peptide A Proteins 0.000 claims description 8
- 125000006850 spacer group Chemical group 0.000 claims description 8
- 230000033115 angiogenesis Effects 0.000 claims description 7
- 125000000524 functional group Chemical group 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 5
- 208000032612 Glial tumor Diseases 0.000 claims description 5
- 206010018338 Glioma Diseases 0.000 claims description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 5
- 208000001132 Osteoporosis Diseases 0.000 claims description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 5
- 235000008206 alpha-amino acids Nutrition 0.000 claims description 5
- 201000010881 cervical cancer Diseases 0.000 claims description 5
- 201000010536 head and neck cancer Diseases 0.000 claims description 5
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 4
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- 108010045325 cyclic arginine-glycine-aspartic acid peptide Proteins 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 238000009206 nuclear medicine Methods 0.000 claims description 4
- 230000000306 recurrent effect Effects 0.000 claims description 4
- 230000036262 stenosis Effects 0.000 claims description 4
- 208000037804 stenosis Diseases 0.000 claims description 4
- 206010027476 Metastases Diseases 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 150000002739 metals Chemical class 0.000 claims description 3
- 230000009401 metastasis Effects 0.000 claims description 3
- 230000005298 paramagnetic effect Effects 0.000 claims description 3
- 230000007170 pathology Effects 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 2
- 238000009007 Diagnostic Kit Methods 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- XLBBKEHLEPNMMF-SSUNCQRMSA-N 129038-42-2 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)[C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCC(O)=O)C1=CC=CC=C1 XLBBKEHLEPNMMF-SSUNCQRMSA-N 0.000 claims 1
- 230000000536 complexating effect Effects 0.000 claims 1
- 108010025752 echistatin Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 37
- 229940024606 amino acid Drugs 0.000 description 20
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 108010031318 Vitronectin Proteins 0.000 description 11
- 102100035140 Vitronectin Human genes 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 230000021164 cell adhesion Effects 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 239000011347 resin Substances 0.000 description 11
- 229920005989 resin Polymers 0.000 description 11
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000010511 deprotection reaction Methods 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 5
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 5
- 102000008946 Fibrinogen Human genes 0.000 description 5
- 108010049003 Fibrinogen Proteins 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229940012952 fibrinogen Drugs 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- -1 inorganic acid anions Chemical class 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- IJKGLSUZCFGUEG-ODPTYIPQSA-N rgdechi Chemical compound C1CCC(C(=O)NCC(=O)N=C(N)NCCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)N1C(=O)C(CC(O)=O)NC(=O)C(CC(O)=O)NC(=O)C(CCSC)NC(=O)CCC1NC(=O)C(CC(O)=O)NC(=O)CNC(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC1=O IJKGLSUZCFGUEG-ODPTYIPQSA-N 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- 238000010647 peptide synthesis reaction Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000700 radioactive tracer Substances 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 238000007363 ring formation reaction Methods 0.000 description 4
- 238000010532 solid phase synthesis reaction Methods 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N THREONINE Chemical compound CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 3
- 239000000816 peptidomimetic Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- HGFOOLONGOBCMP-IBGZPJMESA-N (3s)-3-(6-methoxypyridin-3-yl)-3-[2-oxo-3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]imidazolidin-1-yl]propanoic acid Chemical compound C1=NC(OC)=CC=C1[C@H](CC(O)=O)N1C(=O)N(CCCC=2N=C3NCCCC3=CC=2)CC1 HGFOOLONGOBCMP-IBGZPJMESA-N 0.000 description 2
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 2
- HSXRCEVTMOWCFI-UHFFFAOYSA-N 2-[4,7,10-tris(carboxymethyl)-6-methyl-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound CC1CN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CCN1CC(O)=O HSXRCEVTMOWCFI-UHFFFAOYSA-N 0.000 description 2
- HHLZCENAOIROSL-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound OC(=O)CN1CCNCCN(CC(O)=O)CCN(CC(O)=O)CC1 HHLZCENAOIROSL-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108010069514 Cyclic Peptides Proteins 0.000 description 2
- 102000001189 Cyclic Peptides Human genes 0.000 description 2
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 2
- 208000036566 Erythroleukaemia Diseases 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 208000021841 acute erythroid leukemia Diseases 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 150000001371 alpha-amino acids Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 150000001576 beta-amino acids Chemical class 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 238000003032 molecular docking Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000007781 signaling event Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- PGCYWBNQXSSNDD-NSHDSACASA-N (2s)-2-[bis[2-[bis(carboxymethyl)amino]ethyl]amino]pentanedioic acid Chemical compound OC(=O)CN(CC(O)=O)CCN([C@@H](CCC(=O)O)C(O)=O)CCN(CC(O)=O)CC(O)=O PGCYWBNQXSSNDD-NSHDSACASA-N 0.000 description 1
- KPWIJQVAXKYYJA-QRPNPIFTSA-N (2s)-2-amino-3-phenylpropanoic acid;carbonic acid Chemical compound OC(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 KPWIJQVAXKYYJA-QRPNPIFTSA-N 0.000 description 1
- BSVPOGWJPLMOGO-QRPNPIFTSA-N (2s)-2-amino-3-phenylpropanoic acid;methanesulfonic acid Chemical compound CS(O)(=O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 BSVPOGWJPLMOGO-QRPNPIFTSA-N 0.000 description 1
- BRNJZKOCHZBHSA-QRPNPIFTSA-N (2s)-2-amino-3-phenylpropanoic acid;methylphosphonic acid Chemical compound CP(O)(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 BRNJZKOCHZBHSA-QRPNPIFTSA-N 0.000 description 1
- AZEPORBEOPVRNY-QRPNPIFTSA-N (2s)-2-amino-3-phenylpropanoic acid;nitric acid Chemical compound O[N+]([O-])=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 AZEPORBEOPVRNY-QRPNPIFTSA-N 0.000 description 1
- LENNZWPGZUQFEU-QRPNPIFTSA-N (2s)-2-amino-3-phenylpropanoic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 LENNZWPGZUQFEU-QRPNPIFTSA-N 0.000 description 1
- WAMWSIDTKSNDCU-ZETCQYMHSA-N (2s)-2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)[C@@H](N)C1CCCCC1 WAMWSIDTKSNDCU-ZETCQYMHSA-N 0.000 description 1
- LZOLWEQBVPVDPR-VLIAUNLRSA-N (2s,3r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]butanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@H](OC(C)(C)C)C)C(O)=O)C3=CC=CC=C3C2=C1 LZOLWEQBVPVDPR-VLIAUNLRSA-N 0.000 description 1
- ORKKMGRINLTBPC-HXUWFJFHSA-N (4r)-4-(9h-fluoren-9-ylmethoxycarbonylamino)-5-oxo-5-prop-2-enoxypentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@H](CCC(=O)O)C(=O)OCC=C)C3=CC=CC=C3C2=C1 ORKKMGRINLTBPC-HXUWFJFHSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 1
- WOXWUZCRWJWTRT-UHFFFAOYSA-N 1-amino-1-cyclohexanecarboxylic acid Chemical compound OC(=O)C1(N)CCCCC1 WOXWUZCRWJWTRT-UHFFFAOYSA-N 0.000 description 1
- PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- OMGHIGVFLOPEHJ-UHFFFAOYSA-N 2,5-dihydro-1h-pyrrol-1-ium-2-carboxylate Chemical compound OC(=O)C1NCC=C1 OMGHIGVFLOPEHJ-UHFFFAOYSA-N 0.000 description 1
- KFLKTDAONDZLAN-UHFFFAOYSA-N 2-(n-phenylanilino)acetic acid Chemical compound C=1C=CC=CC=1N(CC(=O)O)C1=CC=CC=C1 KFLKTDAONDZLAN-UHFFFAOYSA-N 0.000 description 1
- SQKUFYLUXROIFM-UHFFFAOYSA-N 2-[2-[carboxymethyl-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methyl]amino]ethyl-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methyl]amino]acetic acid Chemical compound CC1=NC=C(COP(O)(O)=O)C(CN(CCN(CC(O)=O)CC=2C(=C(C)N=CC=2COP(O)(O)=O)O)CC(O)=O)=C1O SQKUFYLUXROIFM-UHFFFAOYSA-N 0.000 description 1
- AQOXEJNYXXLRQQ-KRWDZBQOSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-(4-ethoxyphenyl)propyl]-[2-[bis(carboxymethyl)amino]ethyl]amino]acetic acid Chemical compound CCOC1=CC=C(C[C@@H](CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 AQOXEJNYXXLRQQ-KRWDZBQOSA-N 0.000 description 1
- RZESKRXOCXWCFX-UHFFFAOYSA-N 2-[bis[2-[carboxymethyl-[2-(methylamino)-2-oxoethyl]amino]ethyl]amino]acetic acid Chemical compound CNC(=O)CN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC(=O)NC RZESKRXOCXWCFX-UHFFFAOYSA-N 0.000 description 1
- CZHCGMZJLLOYJW-UHFFFAOYSA-N 2-amino-2-propylpentanoic acid Chemical compound CCCC(N)(C(O)=O)CCC CZHCGMZJLLOYJW-UHFFFAOYSA-N 0.000 description 1
- UBXUDSPYIGPGGP-UHFFFAOYSA-N 2-azaniumyl-2-phenylbutanoate Chemical compound CCC(N)(C(O)=O)C1=CC=CC=C1 UBXUDSPYIGPGGP-UHFFFAOYSA-N 0.000 description 1
- SFYDWLYPIXHPML-UHFFFAOYSA-N 3-nitro-1-(2,4,6-trimethylphenyl)sulfonyl-1,2,4-triazole Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)N1N=C([N+]([O-])=O)N=C1 SFYDWLYPIXHPML-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 101800001224 Disintegrin Proteins 0.000 description 1
- 101001054579 Echis carinatus Disintegrin Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 101710145505 Fiber protein Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- IQUHNCOJRJBMSU-UHFFFAOYSA-N H3HP-DO3A Chemical compound CC(O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 IQUHNCOJRJBMSU-UHFFFAOYSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical group NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHNVWZDZSA-N L-allo-Isoleucine Chemical compound CC[C@@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-UHNVWZDZSA-N 0.000 description 1
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
- DZLNHFMRPBPULJ-VKHMYHEASA-N L-thioproline Chemical compound OC(=O)[C@@H]1CSCN1 DZLNHFMRPBPULJ-VKHMYHEASA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- SGXDXUYKISDCAZ-UHFFFAOYSA-N N,N-diethylglycine Chemical compound CCN(CC)CC(O)=O SGXDXUYKISDCAZ-UHFFFAOYSA-N 0.000 description 1
- CAHKINHBCWCHCF-JTQLQIEISA-N N-acetyl-L-tyrosine Chemical compound CC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CAHKINHBCWCHCF-JTQLQIEISA-N 0.000 description 1
- CIQHWLTYGMYQQR-QMMMGPOBSA-N O(4')-sulfo-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OS(O)(=O)=O)C=C1 CIQHWLTYGMYQQR-QMMMGPOBSA-N 0.000 description 1
- FCIDXUCYDOUKMZ-UHFFFAOYSA-N OC(C1=C[NH+]=[C-]1)=O Chemical compound OC(C1=C[NH+]=[C-]1)=O FCIDXUCYDOUKMZ-UHFFFAOYSA-N 0.000 description 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 206010057469 Vascular stenosis Diseases 0.000 description 1
- VJIXOSFGKGEOQU-QRPNPIFTSA-N acetic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound CC(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 VJIXOSFGKGEOQU-QRPNPIFTSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 238000003352 cell adhesion assay Methods 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 230000035289 cell-matrix adhesion Effects 0.000 description 1
- 210000003570 cell-matrix junction Anatomy 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 108091006116 chimeric peptides Proteins 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- IFQUWYZCAGRUJN-UHFFFAOYSA-N ethylenediaminediacetic acid Chemical compound OC(=O)CNCCNCC(O)=O IFQUWYZCAGRUJN-UHFFFAOYSA-N 0.000 description 1
- OUDSFQBUEBFSPS-UHFFFAOYSA-N ethylenediaminetriacetic acid Chemical compound OC(=O)CNCCN(CC(O)=O)CC(O)=O OUDSFQBUEBFSPS-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- ACYFLOXTAUSYGF-UHFFFAOYSA-N methyl(methylidene)phosphane Chemical compound CP=C ACYFLOXTAUSYGF-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229960001682 n-acetyltyrosine Drugs 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical group N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001855 preneoplastic effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Description
インテグリンは、細胞−細胞接着プロセスおよび細胞−マトリックス接着プロセスにおいて重要な役割を演じるヘテロダイマー膜貫通細胞表面レセプターのファミリーのメンバーである(Hynes, R.O. Cell 1992, 69, 11-25)。これらのレセプターは、定められた組み合わせにおいて非共有結合的に会合するα−サブユニットおよびβ−サブユニットからなる(Eble, J.A. Integrin-Ligand Interaction; Springer: Heidelberg, 1997; pp 1-40)。それらの大部分は、多くの細胞外マトリックスタンパク質(即ちビトロネクチン)(Serini, G.; et al. A sticky business. Exp. Cell. Res. 2005, in press)およびへび毒ディスインテグリン(Ruoslahti, E.; Pierschbacher, M. Cell 1986, 44, 517-518; D'Souza, S.R.; et al. Trends Biochem. Sci. 1991, 16, 246-250; Gould, R.J.; et al. Proc. Soc. Exp. Biol. Med. 1990, 195, 168-171)において見出されるArg−Gly−Asp(RGD)トリアッドを認識する。種々のインテグリンがRGD配列を含有する種々のタンパク質を認識するとしても、いくつかの研究は、高アフィニティーリガンドのRGD配列をフランキングするアミノ酸残基はインテグリン複合体との相互作用のそれらの特異性をモデュレーションすることを証明した。文献で報告された多数の研究にもかかわらず、種々のインテグリンサブタイプに対するリガンド選択性は、依然として難題である。その理由は主として、インテグリンサブタイプの三次元構造の大部分は未知のままであるからである(Marinelli, L.; et al. J. Med. Chem. 2004, 47, 4166-4177)。
本発明は、αvβ3レセプターの強力な且つ選択的アンタゴニストとしてArg−Gly−Asp配列を含有するペプチドまたはペプチド模倣化合物に関し、即ち、本発明の化合物は、新規な抗癌薬物としておよび/またはαvβ3ターゲティングされた治療およびイメージング用の適当なツールとして新規な種類の診断非侵襲性トレーサーとして使用することができる。
本発明の化合物は、下記式(I):
(式中、
AA1は、Cys、Asp、Glu、Lys、Orn、Pen、DabまたはDapの群から選ばれた少なくとも3つの官能基を含有するαアミノ酸であり;
AA2は、Cys、Asp、Glu、Lys、Orn、Pen、DabまたはDapの群から選ばれた少なくとも3つの官能基を含有するαアミノ酸であり;
Lは、0〜2の数のアミノ酸残基からなるリンカー配列、例えば配列PGであり;
(Xaa)nは、nが1〜3の範囲にあるアミノ酸配列であり、該配列はエキスタチンの配列28〜30の配列:MDDに対して実質的に相同性であり;
(Yaa)mは、mが2〜9の範囲にあるアミノ酸配列であり、該配列はエキスタチンのC末端(41〜49)の配列:RNPHKGPATに対して実質的に相同性である)
を有する。
[式中、Aは一般式(I)のペプチドであり;zは0〜5の整数であり;Yはスペーサー鎖であって、それぞれ、ペプチドAに存在する個々のアミノ酸の側鎖に存在する官能基の1つまたはAのN末端(−NH2)基もしくはC末端(−CO2H)基に結合しており且つCに結合したスペーサー鎖であり;zが2〜5の整数であるときは、単位Yは互いに同じであるかまたは異なることができ;
Yは、好ましくは、式(III)
(式中、
r、lおよびqは各々独立に0または1であり、そしてpは独立に0〜10の整数であり、但し、l、rおよびqの少なくとも1つはゼロ以外であるものとし;
Rは水素であり;
R1は水素または−CH3基である)
の基であり;
Cは、スペーサーYにもしくは直接ペプチドAにまたはペプチドAの1つより多くのアミノ酸単位に共有結合で結合したキレート化剤であって、常磁性金属または放射性同位元素を錯化することができるキレート化剤であることができる]
の化合物も指す。
特に、ジエチレントリアミノペンタ酢酸(DTPA)、1,4,7,10−テトラアザシクロドデカン−1,4,7,10−テトラ酢酸(DOTA)、1,4,7,10−テトラアザシクロドデカン−1,4,7−トリ酢酸(DO3A)、[10−(2−ヒドロキシプロピル)−1,4,7,10−テトラアザシクロドデカン−1,4,7−トリ酢酸(HPDO3A)、4−カルボキシ−5,8,11−トリス(カルボキシメチル)−1−フェニル−2−オキサ−5,8,11−トリアザトリデカン−13−酸(BOPTA)、N−[2−[ビス(カルボキシメチル)アミノ]−3−(4−エトキシフェニル)プロピル]−N−[2−[ビス(カルボキシメチル)アミノ]エチルグリシン(EOB−DTPA)、N,Nビス[2[(カルボキシメチル[(メチルカルバモイル)メチル]アミノ]エチル]−グリシン(DTPA−BMA)、2−メチル−1,4,7,10−テトラアザシクロドデカン−1,4,7,10−テトラ酢酸(MCTA)、(α,α’,α”,α”’)−テトラメチル−1,4,7,10−テトラアザシクロドデカン−1,4,7,10−テトラ酢酸(DOTMA)から選ばれるポリアミノポリカルボン酸およびその誘導体の残基からなる群より選ばれるか;または、ポリアミノホスフェート酸リガンドもしくはその誘導体、特に、N,N’−ビス−(ピリドキサル−5−ホスフェート)エチレンジアミン−N,N’−ジ酢酸(DPDP)およびエチレンジニトリロテトラキス(メチルホスホン)酸(EDTP)の残基であるか;またはポリアミノホスホン酸リガンドおよびその誘導体またはポリアミノホスフィン酸およびその誘導体、特に1,4,7,10−テトラアザシクロドデカン−1,4,7,10−テトラキス[メチレン(メチルホスホン)酸および1,4,7,10−テトラアザシクロドデカン−1,4,7,10−テトラキス[メチレン(メチルホスフィン)酸の残基であるか;または大環状キレート化剤、例えばテキサフリン、ポルフィリン、フタロシアニンの残基;またはN,N−ビス[2−[ビス(カルボキシメチル)アミノ]エチル]L−グルタミン酸(DTPA−GLU)もしくはLysとコンジュゲーションされたDTPA(DTPA−Lys)である。他のキレート化基は、刊行物“Radionuclide Pepetide Cancer Therapy”edited by M. Chinol and G. Paganelli, Taylor & Francis CRC Press, 2006(ISBN:082428874)に報告されている。
今後RGDechiと呼ばれる図1に報告された配列を有するペプチドは、環状RGDモチーフおよびリンカーにより接続されたエキスタチンC末端尾部に対応する配列を含有する二官能性キメラ分子である。二官能性分子RGDechiの活性を評価するために、echiL、echi11〜19およびechi8〜19をデザインした(図1)。Echi11〜19およびechi6〜19は、それぞれ11〜19および8〜19RGDechi配列を含みそしてechiLは、RGDechiの線状前駆体に対応する。
Claims (7)
- 環状RGDモチーフおよびスペーサー配列により共有結合で連結された2つのエキスタチンC末端部分を含有する、αvβ3インテグリンに対する選択的アフィニティーを示す、αvβ3インテグリンのアンタゴニスト化合物であって、該アンタゴニスト化合物は、
下記式(I):
(式中、
AA1は、Cys、Asp、Glu、Lys、Orn、Pen、DabまたはDapの群から選ばれた、少なくとも3つの官能基を含有するαアミノ酸であり;
AA2は、Cys、Asp、Glu、Lys、Orn、Pen、DabまたはDapの群から選ばれた、少なくとも3つの官能基を含有するαアミノ酸であり;
Lは、0〜2の数のアミノ酸残基からなるリンカー配列であり;
(Xaa)nは、nが1〜3の範囲にあるアミノ酸配列であり、該配列はエキスタチンの配列28〜30の配列:MDDに相当し;
(Yaa)mは、mが2〜9の範囲にあるアミノ酸配列であり、該配列はエキスタチンのC末端(41〜49)の配列:RNPHKGPATに相当する)
を有する、化合物。 - Lが、配列PGである、請求項1に記載の化合物。
- 式(II):
[式中、Aは一般式(I)のペプチドであり;zは0〜5の整数であり;Yは、スペーサー鎖であって、それぞれ、ペプチドAに存在する個々のアミノ酸の側鎖に存在する官能基の1つまたはAのN末端(−NH2)基もしくはC末端(−CO2H)基に結合しており且つCに結合しているスペーサー鎖であり;zが2〜5の整数であるときは、単位Yは互いに同じであるかまたは異なることができ;
Yは、下記式(III)
(式中、
r、lおよびqは各々独立に0または1であり、そしてpは独立に0〜10の整数であり、但し、l、rおよびqの少なくとも1つはゼロ以外であるものとし;
Rは水素であり;
R1は水素またはメチルである)
を有し;
Cは、スペーサーYにもしくは直接ペプチドAにまたはペプチドAの1つより多くのアミノ酸単位に共有結合で結合したキレート化剤であって、常磁性金属または放射性同位元素または放射性トレーサーを錯化することができるキレート化剤である]
で示される化合物。 - 治療的有効量の請求項1〜3のいずれか1項に記載のαvβ3インテグリンのアンタゴニストおよび薬学的に許容される賦形剤を含む医薬組成物。
- 医薬品として使用するための請求項1〜3のいずれか1項に記載のαvβ3インテグリンのアンタゴニスト化合物。
- 乳癌、筋骨格腫瘍、メラノーマ、頭部および頸部癌、ヒトグリオーマ、子宮頸部癌、血管再発狭窄症、骨粗鬆症、慢性関節リウマチからなる群より選択される血管新生および転移に関する病状の処置に使用するための請求項1〜3のいずれか1項に記載のαvβ3インテグリンのアンタゴニスト化合物。
- 乳癌、筋骨格腫瘍、メラノーマ、頭部および頸部癌、ヒトグリオーマ、子宮頸部癌、血管再発狭窄症、骨粗鬆症、慢性関節リウマチの血漿中の早期の検出、MRIによる診断又は核医学のための診断キットの一部としての請求項1〜3のいずれか1項に記載のα v β 3 インテグリンのアンタゴニスト化合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72529405P | 2005-10-12 | 2005-10-12 | |
US60/725,294 | 2005-10-12 | ||
PCT/EP2006/009733 WO2007042241A2 (en) | 2005-10-12 | 2006-10-09 | Selective alfavbeta3 receptor peptide antagonist for therapeutic and diagnostic applications |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009512643A JP2009512643A (ja) | 2009-03-26 |
JP5221355B2 true JP5221355B2 (ja) | 2013-06-26 |
Family
ID=37943159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008534912A Active JP5221355B2 (ja) | 2005-10-12 | 2006-10-09 | 治療及び診断用途のための選択的αvβ3レセプターペプチドアンタゴニスト |
Country Status (7)
Country | Link |
---|---|
US (2) | US8546526B2 (ja) |
EP (1) | EP1934248B1 (ja) |
JP (1) | JP5221355B2 (ja) |
CA (1) | CA2625436C (ja) |
ES (1) | ES2413056T3 (ja) |
PL (1) | PL1934248T3 (ja) |
WO (1) | WO2007042241A2 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2625436C (en) * | 2005-10-12 | 2016-01-05 | Annarita Del Gatto | Selective alfavbeta3 receptor peptide antagonist for therapeutic and diagnostic applications |
US9775803B2 (en) | 2011-10-19 | 2017-10-03 | Samsung Electronics Co., Ltd. | Liposome comprising elastin-like polypeptide and tumor cell targeting material and use thereof |
MA40998A (fr) | 2014-11-21 | 2017-09-26 | Ophirex Inc | Thérapies contre une envenimation, ainsi que compositions, systèmes et kits pharmaceutiques associés |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19653036A1 (de) * | 1996-12-19 | 1998-06-25 | Merck Patent Gmbh | Cyclopeptidderivate |
CA2625436C (en) * | 2005-10-12 | 2016-01-05 | Annarita Del Gatto | Selective alfavbeta3 receptor peptide antagonist for therapeutic and diagnostic applications |
-
2006
- 2006-10-09 CA CA2625436A patent/CA2625436C/en active Active
- 2006-10-09 PL PL06806112T patent/PL1934248T3/pl unknown
- 2006-10-09 WO PCT/EP2006/009733 patent/WO2007042241A2/en active Application Filing
- 2006-10-09 EP EP06806112.6A patent/EP1934248B1/en active Active
- 2006-10-09 US US12/089,709 patent/US8546526B2/en active Active
- 2006-10-09 ES ES06806112T patent/ES2413056T3/es active Active
- 2006-10-09 JP JP2008534912A patent/JP5221355B2/ja active Active
-
2013
- 2013-08-30 US US14/016,020 patent/US9309288B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US9309288B2 (en) | 2016-04-12 |
WO2007042241A3 (en) | 2007-11-29 |
CA2625436A1 (en) | 2007-04-19 |
US8546526B2 (en) | 2013-10-01 |
JP2009512643A (ja) | 2009-03-26 |
WO2007042241A2 (en) | 2007-04-19 |
US20140094412A1 (en) | 2014-04-03 |
PL1934248T3 (pl) | 2013-09-30 |
EP1934248A2 (en) | 2008-06-25 |
ES2413056T3 (es) | 2013-07-15 |
US20080213190A1 (en) | 2008-09-04 |
EP1934248B1 (en) | 2013-05-01 |
CA2625436C (en) | 2016-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2008260326B2 (en) | Cyclic peptide CXCR4 antagonists | |
Thumshirn et al. | Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid‐phase peptide synthesis and chemoselective oxime ligation | |
Heckmann et al. | Design and chemical synthesis of integrin ligands | |
EP0677060A1 (en) | Peptide inhibitors of cell adhesion | |
HUT72889A (en) | Radiolabeled platelet gpiib/iiia receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders | |
CN113474045A (zh) | Pd-l1特异性的双环肽配体 | |
KR20050034716A (ko) | 성장 호르몬 방출 펩타이드 | |
Poschenrieder et al. | The influence of different metal-chelate conjugates of pentixafor on the CXCR4 affinity | |
Amso et al. | Structure activity relationship study on the peptide hormone preptin, a novel bone-anabolic agent for the treatment of osteoporosis | |
CN112585157A (zh) | 用于结合整联蛋白αvβ3的肽配体 | |
US9309288B2 (en) | Selective αvβ3 receptor peptide antagonist for therapeutic and diagnostic applications | |
Hung et al. | Structure-activity relationship study of the tumour-targeting peptide A20FMDV2 via modification of Lys16, Leu13, and N-and/or C-terminal functionality | |
Amso et al. | Synthesis and in vitro bone cell activity of analogues of the cyclohexapeptide dianthin G | |
CA2133090A1 (en) | Endothelin antagonists ii | |
TW517063B (en) | Biotin derivatives | |
EP3846858A1 (en) | Alpha(v)beta(6) integrin-binding peptides and methods of use thereof | |
Auernheimer et al. | Radio‐Analytical Determination of the Coating Efficiency of Cyclic RGD Peptides | |
Tang | Identification, Characterization and Optimization of Integrin α v β 6-Targeting Peptides for the Development of PET Imaging Agents | |
CA3008052C (en) | Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes | |
Anselmi | Peptidomimetic ligands for tuning integrin-mediated signalling: rational design, synthesis and theranostic applications | |
Jain | Design and Synthesis of Beta-Hairpin Peptidomimetics for Modulating Integrin Mediated Cell Adhesion, Abeta Fibrillogenesis and p53-MDM2 Protein-Protein Interactions | |
NZ260946A (en) | Peptide cell adhesion inhibitors, pharmaceutical compositions, and diagnosis of disease | |
KR20060121244A (ko) | 개선된 가스트린 방출 펩티드 화합물 | |
MX2011002937A (es) | Agentes de contraste y terapeuticos bicílicos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090930 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20110502 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110502 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120131 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120501 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120510 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120522 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120529 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120702 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120731 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121029 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121105 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121121 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121129 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121220 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121228 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130130 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130226 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130307 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160315 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5221355 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |